newsfilter
← Latest News
PR Newswire·

UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022

Late-breaking 52-week data on investigational bimekizumab in the treatment of adults with active psoriatic arthritis and active axial spondyloarthritis to be presentedNew data on CIMZIA® (certolizumab pegol) and